

# Emmanouil Saloustros

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2626640/publications.pdf>

Version: 2024-02-01

97  
papers

6,395  
citations

126907

33  
h-index

79698

73  
g-index

106  
all docs

106  
docs citations

106  
times ranked

10297  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	27.8	1,099
2	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34.	6.2	711
3	Breast Cancer Risk Genes Association Analysis in More than 113,000 Women. <i>New England Journal of Medicine</i> , 2021, 384, 428-439.	27.0	532
4	Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. <i>Nature Genetics</i> , 2014, 46, 438-443.	21.4	383
5	Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review). <i>International Journal of Oncology</i> , 2016, 48, 869-885.	3.3	302
6	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	21.4	289
7	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	21.4	265
8	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. <i>Nature Genetics</i> , 2018, 50, 968-978.	21.4	184
9	Genetic insights into biological mechanisms governing human ovarian ageing. <i>Nature</i> , 2021, 596, 393-397.	27.8	183
10	Global cancer control: responding to the growing burden, rising costs and inequalities in access. <i>ESMO Open</i> , 2018, 3, e000285.	4.5	169
11	Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). <i>Annals of Oncology</i> , 2015, 26, 1333-1340.	1.2	153
12	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	21.4	120
13	Paclitaxel and docetaxel in the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2603-2616.	1.8	105
14	Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPe). <i>ESMO Open</i> , 2021, 6, 100096.	4.5	104
15	Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?. <i>Breast</i> , 2015, 24, 201-207.	2.2	97
16	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	12.8	90
17	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	12.8	88
18	The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. <i>Gynecologic Oncology</i> , 2016, 141, 454-460.	1.4	85

#	ARTICLE	IF	CITATIONS
19	Prevalence of <i>BRCA1</i> and <i>BRCA2</i> mutations in Ashkenazi Jewish families with breast and pancreatic cancer. <i>Cancer</i> , 2012, 118, 493-499.	4.1	83
20	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2019, 48, 795-806.	1.9	81
21	Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. <i>Breast Cancer Research</i> , 2011, 13, R60.	5.0	74
22	Large-cell calcifying Sertoli cell tumors of the testes in pediatrics. <i>Current Opinion in Pediatrics</i> , 2012, 24, 518-522.	2.0	71
23	<i>Morganella morganii</i> Infections in a General Tertiary Hospital. <i>Infection</i> , 2006, 34, 315-321.	4.7	65
24	Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019, 120, 647-657.	6.4	52
25	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. <i>JAMA Oncology</i> , 2022, 8, e216744.	7.1	51
26	The cAMP pathway and the control of adrenocortical development and growth. <i>Molecular and Cellular Endocrinology</i> , 2012, 351, 28-36.	3.2	48
27	The care of adolescents and young adults with cancer: results of the ESMO/SIOPE survey. <i>ESMO Open</i> , 2017, 2, e000252.	4.5	48
28	Docetaxel in the treatment of advanced non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1207-1222.	2.4	47
29	Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer. <i>Cancer Letters</i> , 2016, 370, 302-312.	7.2	47
30	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. <i>American Journal of Human Genetics</i> , 2020, 107, 837-848.	6.2	39
31	Pancreatic Ductal and Acinar Cell Neoplasms in Carney Complex: A Possible New Association. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1888-E1895.	3.6	38
32	KCNJ5 mutations in the National Institutes of Health cohort of patients with primary hyperaldosteronism: an infrequent genetic cause of Conn's syndrome. <i>Endocrine-Related Cancer</i> , 2012, 19, 255-260.	3.1	38
33	Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 105-113.	2.5	37
34	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	1.3	32
35	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. <i>Nature Communications</i> , 2020, 11, 312.	12.8	30
36	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 38.	5.2	28

#	ARTICLE	IF	CITATIONS
37	Prkar1a gene knockout in the pancreas leads to neuroendocrine tumorigenesis. <i>Endocrine-Related Cancer</i> , 2017, 24, 31-40.	3.1	26
38	<i>Candida albicans</i> versus non- <i>albicans</i> bloodstream infection in patients in a tertiary hospital: An analysis of microbiological data. <i>Scandinavian Journal of Infectious Diseases</i> , 2008, 40, 414-419.	1.5	25
39	Extending the clinical phenotype associated with biallelic <i>NTHL1</i> germline mutations. <i>Clinical Genetics</i> , 2018, 94, 588-589.	2.0	23
40	Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 851-863.	1.8	21
41	Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). <i>Annals of Oncology</i> , 2016, 27, 1873-1878.	1.2	21
42	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , 2021, 12, 1078.	12.8	19
43	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 623-642.	2.5	19
44	Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group. <i>Clinical Breast Cancer</i> , 2018, 18, 88-94.	2.4	17
45	A nosocomial, foodborne outbreak of <i>Salmonella</i> Enterica serovar Enteritidis in a University hospital in Greece: the importance of establishing HACCP systems in hospital catering. <i>Journal of Hospital Infection</i> , 2007, 66, 194-196.	2.9	16
46	Is IGSF1 involved in human pituitary tumor formation?. <i>Endocrine-Related Cancer</i> , 2015, 22, 47-54.	3.1	16
47	Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	4.2	16
48	Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 581-585.	2.5	15
49	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. <i>Breast Cancer Research</i> , 2022, 24, 2.	5.0	15
50	Cytokeratin 19-positive circulating tumor cells in early breast cancer prognosis. <i>Future Oncology</i> , 2010, 6, 209-219.	2.4	14
51	Care of adolescents and young adults with cancer in Asia: results of an ESMO/SIOPE/SIOP Asia survey. <i>ESMO Open</i> , 2019, 4, e000467.	4.5	14
52	Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk. <i>International Journal of Cancer</i> , 2020, 146, 2130-2138.	5.1	13
53	Common Susceptibility Loci for Male Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 453-461.	6.3	12
54	Celecoxib reduces glucocorticoids in vitro and in a mouse model with adrenocortical hyperplasia. <i>Endocrine-Related Cancer</i> , 2016, 23, 15-25.	3.1	11

#	ARTICLE	IF	CITATIONS
55	Advanced Non-Small-Cell Lung Cancer in the Elderly. <i>Clinical Lung Cancer</i> , 2009, 10, 158-167.	2.6	10
56	Anti-CV2 associated cerebellar degeneration after complete response to chemoradiation of head and neck carcinoma. <i>Journal of Neuro-Oncology</i> , 2010, 97, 291-294.	2.9	10
57	Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG). <i>Breast Cancer Research and Treatment</i> , 2014, 148, 591-597.	2.5	10
58	Lymph Node Cellular Dynamics in Cancer and HIV: What Can We Learn for the Follicular CD4 (Tfh) Cells?. <i>Frontiers in Immunology</i> , 2018, 9, 2233.	4.8	10
59	Genetic Evidence for the Association between Schizophrenia and Breast Cancer. <i>Journal of Psychiatry and Brain Science</i> , 2018, 3, .	0.5	10
60	Haploinsufficiency for either one of the type-II regulatory subunits of protein kinase A improves the bone phenotype of Prkar1a+/â mice. <i>Human Molecular Genetics</i> , 2015, 24, 6080-6092.	2.9	9
61	Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group. <i>British Journal of Cancer</i> , 2017, 117, 164-170.	6.4	9
62	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. <i>British Journal of Cancer</i> , 2021, 125, 1135-1145.	6.4	9
63	Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: a pooled analysis of randomized controlled trials by the Hellenic Academy of Oncology. <i>Oncotarget</i> , 2019, 10, 1209-1216.	1.8	9
64	Vaccine third dose and cancer patients: necessity or luxury?. <i>ESMO Open</i> , 2021, 6, 100306.	4.5	9
65	Hematopoietic neoplasms in Prkar2a-deficient mice. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 143.	8.6	8
66	Lung cancer in the era of Greek economic crisis. <i>Lung Cancer</i> , 2014, 86, 112-113.	2.0	7
67	BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects. <i>International Journal of Cancer</i> , 2020, 147, 1334-1342.	5.1	7
68	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , 2021, 23, 86.	5.0	7
69	Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer. <i>Annals of Oncology</i> , 2010, 21, 1729-1730.	1.2	6
70	Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 217-223.	2.3	6
71	Bone Abnormalities in Mice with Protein Kinase A (PKA) Defects Reveal a Role of Cyclic AMP Signaling in Bone Stromal Cell-Dependent Tumor Development. <i>Hormone and Metabolic Research</i> , 2016, 48, 714-725.	1.5	6
72	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. <i>Human Genetics and Genomics Advances</i> , 2021, 2, 100042.	1.7	6

#	ARTICLE	IF	CITATIONS
73	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. <i>American Journal of Human Genetics</i> , 2021, 108, 1190-1203.	6.2	6
74	Rare germline copy number variants (CNVs) and breast cancer risk. <i>Communications Biology</i> , 2022, 5, 65.	4.4	6
75	Favorable Clinical Course of Patients Experiencing Bevacizumab-Induced Proteinuria. <i>Case Reports in Oncology</i> , 2010, 3, 368-371.	0.7	5
76	Celecoxib treatment of fibrous dysplasia (FD) in a human FD cell line and FD-like lesions in mice with protein kinase A (PKA) defects. <i>Molecular and Cellular Endocrinology</i> , 2017, 439, 165-174.	3.2	5
77	Two truncating variants in FANCC and breast cancer risk. <i>Scientific Reports</i> , 2019, 9, 12524.	3.3	5
78	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. <i>British Journal of Cancer</i> , 2021, 124, 842-854.	6.4	5
79	Coffee Drinking and Mortality. <i>New England Journal of Medicine</i> , 2012, 367, 575-577.	27.0	4
80	Potential Late Effect of Gonadotropin-Releasing Hormone Agonists in Combination With Chemotherapy for Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3311-3312.	1.6	3
81	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. <i>Scientific Reports</i> , 2020, 10, 9688.	3.3	2
82	Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 181-193.	2.0	2
83	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. <i>Scientific Reports</i> , 2021, 11, 19787.	3.3	2
84	Physicians'™ experience, practice and education, on genetic testing and genetic counseling: a nationwide survey study in Greece. <i>Familial Cancer</i> , 2022, 21, 479-487.	1.9	1
85	Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group. <i>Current Oncology</i> , 2022, 29, 1237-1251.	2.2	1
86	Screening and Detection of Breast Cancer and Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1032.	7.4	0
87	Case 17-2011: A Woman with a Mass in the Breast and Overlying Skin Changes. <i>New England Journal of Medicine</i> , 2011, 365, 1259-1260.	27.0	0
88	Docetaxel (D), Gemcitabine (G) and Bevacizumab (BEV) as Salvage Chemotherapy (CT) for HER-2 Negative Metastatic Breast Cancer (MBC). <i>Annals of Oncology</i> , 2012, 23, ix139.	1.2	0
89	Palliative chemotherapy for patients with breast cancer. <i>Lancet Oncology</i> , The, 2015, 16, 1453-1454.	10.7	0
90	Bevacizumab plus dose-dense neoadjuvant FEC followed by docetaxel chemotherapy in patients with HER2-negative breast cancer: a multicentre, phase 2 study by the Hellenic Oncology Research Group. <i>Annals of Oncology</i> , 2016, 27, vi62.	1.2	0

#	ARTICLE	IF	CITATIONS
91	Customisation of therapeutic strategy in metastatic colorectal cancer by use of liquid biopsies: Updated results of an observational study. <i>Annals of Oncology</i> , 2019, 30, vii13.	1.2	0
92	Abstract 1360: A mouse model of double heterozygosity for protein kinase A regulatory subunits promotes osteoblastic differentiation of cAMP-induced bone tumors. , 2012, , .		0
93	Abstract 954: COX-2 inhibition reduces bone tumor growth in animal models:A role for celecoxib treatment in cAMP/protein kinase A-induced tumors. , 2012, , .		0
94	Abstract 3854: Novel hematopoietic neoplasms in prkar2a- deficient mice.. , 2013, , .		0
95	Abstract LB-89: Germ-line and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. , 2014, , .		0
96	Abstract 3422: The influence of genetic and clinical factors on the outcome following a diagnosis of small cell carcinoma of the ovary, hypercalcemic type. , 2016, , .		0
97	Abstract 3740: The pursue of genetic mechanisms underlying supreme response to pazopanib treatment. , 2017, , .		0